NCCN Guidelines

Guidelines

• NCCN Guidelines Version 1.2025

Evidence Blocks

• NCCN Guidelines with Evidence Blocks Version 1.2025

Guidelines for Patients

• Multiple Myeloma-English Version 2023

• Multiple Myeloma-Chinese Version 2023

• Multiple Myeloma-French Version 2023

• Multiple Myeloma-Korean Version 2022

• Multiple Myeloma-Spanish Version 2023

Educational Events and Programs

Calendar of Events

Continuing Education

• Revolutionizing Hematologic Cancer Treatment: The Promise of Bispecific T-Cell Engagers

• Navigating the Challenges: Effective Management of Toxicities in CAR T-Cell Therapies

• Navigating Change: Best Practices for Integrating WHO/ICC Classification Systems in the Management of Hematologic Malignancies

• Management of Newly Diagnosed Multiple Myeloma Based on Risk Stratification

• Incorporating Immunotherapeutic Strategies in the Management of Relapsed/Refractory Multiple Myeloma

• Tackling Inequities in Multiple Myeloma: Practical Steps for Improving Access and Quality of Care

• Bone Disease Management and Infections in Multiple Myeloma

• Bispecific Antibodies: A New Frontier in Immunotherapy

• Updates to the Management of Multiple Myeloma

International

Disclosures

• Disclosure Policy

• Panel Member Disclosures

• Panel Member Disclosures by Meeting Date

• End User License Agreement